FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 646 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR 21-Month-Old Girl Celebrates After Beating Stage 4 Cancer May 24, 2019 Cancer in My Community: Encouraging Cancer Screening in Estonia May 23, 2023 EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin April 14, 2022 Young Mom With Metastatic Breast Cancer Travels To Mexico For Alternative... November 26, 2019 Load more HOT NEWS Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... MGUS to Myeloma: Study Suggests Risk of Progression Can Change Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press...
